Publications
Cardiovascular and Diabetes
| Cardiovascular and Diabetes | |
|---|---|
| Gaw JR, Crowley S, Monagle P, Jones S, Newall F (2013) The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. Thromb Res;132(1):26-31 CLICK HERE TO READ | Aristides M, Weston A, Fitzgerald P, Le Reun C, Maniadakis N. 2004. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multi-country application of a discrete choice experiment. Value in Health 7:442–454. CLICK HERE TO READ |
| Tilden D, Pascoe K, Higashi MK, Marelli C, Kennedy L, Scheijbeler H, Aristides M. Towards a modelled economic evaluation to identify the optimal population for screening of coronary artery disease. pcv78, Saturday, October 28, 2006, ISPOR ninth annual European congress, Copenhagen, Denmark) CLICK HERE TO READ | Ashley ED, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy. 2012 32, 890 CLICK HERE TO READ |
| Tahami Monfared AA, O’Sullivan AK, Rotstein C, Papadopoulos G. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol 2012; 23(2):59–64. CLICK HERE TO READ | O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673 CLICK HERE TO READ |
| Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G. Comparative Survival and Cost of Therapy: Posaconazole vs. Standard Antifungals in Treatment of Invasive, Refractory Aspergillosis. Curr Med Res Opin, 2010 Oct 26 (10): 2457-64 CLICK HERE TO READ | Kielhorn A, Rubbert A, Porter D, De Vita S, Brown B, Aristides M, Aultman R, Jost F. Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-european analysis. (par10, Saturday, May 20, 2006, ISPOR eleventh annual international meeting, Philadelphia, pa) CLICK HERE TO READ |
| O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole Versus Fluconazole in the Prevention of Invasive Fungal Infections Among Patients with Graft-versus-Host Disease in the US. Am J Health Syst Pharm Jan 15 2012. CLICK HERE TO READ | Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology. 2010;78(3-4):172-80. Epub 2010 Apr 23. CLICK HERE TO READ |
| Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Danna R, Papadopoulos G. The Economic Costs to United States Hospitals of Invasive Fungal Infections Transplant Patients. Am J Infect Control 2010 Oct 19 CLICK HERE TO READ | O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673 CLICK HERE TO READ |
| Aristides M, Kotchie R, Nielsen S, Townsend C, Valentine WJ, Scheijbeler H. Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting. (pdb23, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland) CLICK HERE TO READ | Aristides M, Kotchie R, Nielsen S, Aagren M, Valentine W, Goodall G. Cost-effectiveness of insulin detemir versus nph for type 1 diabetes patients in an Italian setting. a meta-analysis. (pdb20, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland). CLICK HERE TO READ |
| Brown B, Odeyemi IA, Christova L, Aristides M, Tilden D. Using the general practice research database to estimate the incidence, prevalence and management of hyperhidrosis in the United Kingdom. (psn1, Sunday, November 06, 2005, ISPOR eighth European congress, Florence, Italy). CLICK HERE TO READ | Crowley S, Tognarini D, Desmond P, Lees M, Saal G (2002) Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol. 2002;17(2):153-64. CLICK HERE TO READ |
| Shalom B, Langford J, Berry G, Collins D, Lauchlan R, Stewart K, Aristides M, Dobson M. 2000. Economic impact of increased clinical intervention rates in community pharmacy – a randomised trial of the effect of educational and a professional allowance. Pharmacoeconomics 18:459–468. CLICK HERE TO READ |
Central Nervous System
| Central Nervous System | |
|---|---|
| Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88. CLICK HERE TO READ | Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine Frequency and Health Utilities: Findings from a multi-site survey. Value In Health 2008, 11, 2, 315-321 CLICK HERE TO READ |
| Cottrell S, Allen E, Pascoe K, Sullivan T, LeReun C, Brown J, Lorenzo M, Aristides M. Preference and willingness-to-pay study to assess the value of atomoxetine using discrete choice analysis: uk parents perspective. (pmh48, Monday, May 28, 2007, ISPOR twelfth annual international meeting, arlington, va, usa) CLICK HERE TO READ | Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine Frequency and Health Utilities: Findings from a multi-site survey. Value In Health 2008, 11, 2, 315-321 CLICK HERE TO READ |
| Diamond M, Dahlöf C, Papadopoulos G, Neto, Wu S-C,. Topiramate improves health-related quality of life when used to prevent migraine. Headache 45, 1023-1030, 2005 CLICK HERE TO READ | Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88. CLICK HERE TO READ |
| Stahl, SM, Markowitz, JS, Papadopoulos, G, Sadik, K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion 20(4) 517-524, 2004 CLICK HERE TO READ | Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost effectiveness of migraine prevention: the case of topiramate in the United Kingdom. Cephalalgia 26, 1473-82, 2006 CLICK HERE TO READ |
| Markowitz JS, Gutterman E, Papadopoulos G. Health Related Quality of Life Among Caregivers with persons with Alzheimer’s Disease. Alzheimers Disease and Associated Disorders 17, 209-214, 2003 CLICK HERE TO READ | Markowitz JS, Gutterman EM, Lilieneld S, Papadopoulos G. Sleep-Related Outcomes in Persons with Mild to Moderate Alzheimer's disease in a Placebo-Controlled Trial of Galantamine. Sleep 26(5), 602-606, 2003 CLICK HERE TO READ |
| Caro JJ, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, Torfs K. To What Degree Does Cognitive Impairment in Alzheimer’s Disease Predict Dependence of Patients on Caregivers. BMC Neurology 2:6; 2002 CLICK HERE TO READ | Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G for the AHEAD Study Group. Economic evaluation of galantamine for the treatment of mild to moderate Alzheimer’s disease in the United States Current Therapeutics 25(6), 1806-25, 2003 CLICK HERE TO READ |
| Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. CMRO 22, 6, 1021-1029, 2006 CLICK HERE TO READ | Tilden D, Aristides M, Meddis D, Burns T. 2002. An economic evaluation of quetiapine and haloperidol in the treatment of schizophrenic patients partially responsive to previous antipsychotics. Clinical Therapeutics 24:1648–1667. CLICK HERE TO READ |
Economic modelling and Cost-effectiveness
| Economic modelling and Cost-effectiveness | |
|---|---|
| Gaw JR, Crowley S, Monagle P, Jones S, Newall F (2013) The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. Thromb Res;132(1):26-31 CLICK HERE TO READ | O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673 CLICK HERE TO READ |
| Ashley ED, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy. 2012 32, 890 CLICK HERE TO READCLICK HERE TO READ | Tahami Monfared AA, O’Sullivan AK, Rotstein C, Papadopoulos G. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol 2012; 23(2):59–64. CLICK HERE TO READ |
| O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole Versus Fluconazole in the Prevention of Invasive Fungal Infections Among Patients with Graft-versus-Host Disease in the US. Am J Health Syst Pharm Jan 15 2012. CLICK HERE TO READ | Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology. 2010;78(3-4):172-80. Epub 2010 Apr 23. CLICK HERE TO READ |
| Shih ST, Crowley S, Sheu JC (2010) Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc;109(1):39-55. CLICK HERE TO READ | Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G. Comparative Survival and Cost of Therapy: Posaconazole vs. Standard Antifungals in Treatment of Invasive, Refractory Aspergillosis. Curr Med Res Opin, 2010 Oct 26 (10): 2457-64 CLICK HERE TO READ |
| Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Danna R, Papadopoulos G. The Economic Costs to United States Hospitals of Invasive Fungal Infections Transplant Patients. Am J Infect Control 2010 Oct 19 CLICK HERE TO READ | O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673 CLICK HERE TO READ |
| Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88. CLICK HERE TO READ | Cottrell S, Walker M, Scheijbeler H, Christova L, Hertel N, Hass B, Behrens M, Roux E, Amonkar M, Aristides M. 2008. Impact of brain metastases on health care costs associated with the management of patients with metastatic breast cancer in France and Germany. Eur J Cancer. 6(7):176. CLICK HERE TO READ |
| Aristides M, Kotchie R, Nielsen S, Townsend C, Valentine WJ, Scheijbeler H. Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting. (pdb23, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland) CLICK HERE TO READ | Geary U, Lewis G, Aultman R, Aristides M.A cost utility analysis of maintenance rituximab for the treatment of relapsed/refractory follicular non hodgkins lymphoma (nhl) in the uk. (pcn46, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland). CLICK HERE TO READ |
| Tilden D, Pascoe K, Higashi MK, Marelli C, Kennedy L, Scheijbeler H, Aristides M. Towards a modelled economic evaluation to identify the optimal population for screening of coronary artery disease. pcv78, Saturday, October 28, 2006, ISPOR ninth annual European congress, Copenhagen, Denmark) CLICK HERE TO READ | Kielhorn A, Rubbert A, Porter D, De Vita S, Brown B, Aristides M, Aultman R, Jost F. Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-european analysis. (par10, Saturday, May 20, 2006, ISPOR eleventh annual international meeting, Philadelphia, pa) CLICK HERE TO READ |
| Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost effectiveness of migraine prevention: the case of topiramate in the United Kingdom. Cephalalgia 26, 1473-82, 2006 CLICK HERE TO READ | Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Review of Pharmacoeconomics and Outcomes Research 4(1):27–38. CLICK HERE TO READ |
| Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G for the AHEAD Study Group. Economic evaluation of galantamine for the treatment of mild to moderate Alzheimer’s disease in the United States Current Therapeutics 25(6), 1806-25, 2003 CLICK HERE TO READ | George Papadopoulos, Sarah Griffin, Hemant Rathi, Amit Gupta, Bhavna Sharma & Dirk van Bavel.
A Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee – an Australian perspective. CLICK HERE TO READ |
| George Papadopoulos, Sarah Griffin, Hemant Rathi, Amit Gupta, Bhavna Sharma & Dirk van Bavel (2022). Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee – an Australian perspective, Journal of Medical Economics, 25:1, 712-721, DOI: 10.1080/13696998.2022.2078574 CLICK HERE TO READ |
Meta-analyses and HTA related
| Meta-analyses and HTA related | |
|---|---|
| Stahel, J.L. Pujol, G. Scagliotti, J. Vansteenkiste, N. Thatcher, C. Manegold, N. van Zandwijk, JY Douillard, M. Aristides Analysis of survival outcomes: Sub-Analysis of Gemcitabine plus Cisplatin (GC) compared with other Cisplatin-containing regimens in the Treatment of Advanced Non-Small-Cell Lung Cancer. R. International Congress of on Anti Cancer Treatment (ICACT). The congress is scheduled from 5th to 8th February 2008 in Paris. CLICK HERE TO READ | Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice? App. Health Econ Health Policy. 2015: 13(3); 291-302. CLICK HERE TO READ |
| Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007, ISPOR tenth annual european congress, Dublin, Ireland) CLICK HERE TO READ | Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80. CLICK HERE TO READ |
| Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80. CLICK HERE TO READ | Dunt DR, Crowley S, Day NA. Is prevention really better than cure? Parameters of the debate and implications for program evaluation design. Health Promot. Int. (1995) 10 (4): 325-334 CLICK HERE TO READ |
| Smith CS, Crowley S (1995). Labor force planning issues for allied health in Australia. J Allied Health; 24(4):249-65. CLICK HERE TO READ | Aristides M, Mitchell A. 1994. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics 6:196–201. CLICK HERE TO READ |
| Richardson J, Crowley S. (1994) Optimum alcohol taxation: balancing consumption and external costs. Health Econ;3(2):73-87. CLICK HERE TO READ | Balding C, Crowley S, Collopy BT.ACHS Care Evaluation Program Hospital-Wide Clinical Indicator Seminar. Aust Clin Rev. 1990;10(2):80-2 CLICK HERE TO READ |
Oncology
| Oncology | |
|---|---|
| Aristides Mike, Barlev Arie, Barber Beth, Gijsen Merel, Quinn Casey. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health and Quality of Life Outcomes. 2015, 13:181 DOI: 10.1186/s12955-015-0377-3. CLICK HERE TO READ | Shih ST, Crowley S, Sheu JC (2010) Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc;109(1):39-55. CLICK HERE TO READ |
| Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007 CLICK HERE TO READ | Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80. CLICK HERE TO READ |
| Aristides M, von der Maase H, Roberts T, Brown A, Kielhorn A, Bhalla S. 2005. Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer. European Journal of Cancer Care 14:141–2. CLICK HERE TO READ | Cottrell S, Walker M, Scheijbeler H, Christova L, Hertel N, Hass B, Behrens M, Roux E, Amonkar M, Aristides M. 2008. Impact of brain metastases on health care costs associated with the management of patients with metastatic breast cancer in France and Germany. Eur J Cancer. 6(7):176. CLICK HERE TO READ |
| Geary U, Lewis G, Aultman R, Aristides M.A cost utility analysis of maintenance rituximab for the treatment of relapsed/refractory follicular non hodgkins lymphoma (nhl) in the uk. (pcn46, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland). CLICK HERE TO READ | Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Review of Pharmacoeconomics and Outcomes Research 4(1):27–38. CLICK HERE TO READ |
| Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice? App. Health Econ Health Policy. 2015: 13(3); 291-302. CLICK HERE TO READ | Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N. 2003. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. European Journal of Health Economics 4(3): 216–221. CLICK HERE TO READ |
Utility and Preference Studies
| Utility and Preference Studies | |
|---|---|
| Stahel, J.L. Pujol, G. Scagliotti, J. Vansteenkiste, N. Thatcher, C. Manegold, N. van Zandwijk, JY Douillard, M. Aristides Analysis of survival outcomes: Sub-Analysis of Gemcitabine plus Cisplatin (GC) compared with other Cisplatin-containing regimens in the Treatment of Advanced Non-Small-Cell Lung Cancer. R. International Congress of on Anti Cancer Treatment (ICACT). The congress is scheduled from 5th to 8th February 2008 in Paris. CLICK HERE TO READ | Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice? App. Health Econ Health Policy. 2015: 13(3); 291-302. CLICK HERE TO READ |
| Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007, ISPOR tenth annual european congress, Dublin, Ireland) CLICK HERE TO READ | Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80. CLICK HERE TO READ |
| Dunt DR, Crowley S, Day NA. Is prevention really better than cure? Parameters of the debate and implications for program evaluation design. Health Promot. Int. (1995) 10 (4): 325-334 CLICK HERE TO READ | Smith CS, Crowley S (1995). Labor force planning issues for allied health in Australia. J Allied Health; 24(4):249-65. CLICK HERE TO READ |
| Aristides M, Mitchell A. 1994. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics 6:196–201. CLICK HERE TO READ | Richardson J, Crowley S. (1994) Optimum alcohol taxation: balancing consumption and external costs. Health Econ;3(2):73-87. CLICK HERE TO READ |
| Balding C, Crowley S, Collopy BT.ACHS Care Evaluation Program Hospital-Wide Clinical Indicator Seminar. Aust Clin Rev. 1990;10(2):80-2 CLICK HERE TO READ |
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.